Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Slides:

Advertisements

Similar presentations

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome Paul Steinberg, MDa, Bruce E.

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: The German Infant Nutritional Intervention Study, a randomized.

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Heredity, pet ownership, and confounding control in a population-based birth cohort Catarina Almqvist, MD, PhDa,b, Ann-Charlotte Egmar, RNa, Marianne.

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A.

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Quantitative IgE antibody assays in allergic diseases

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Richard L. ZuWallack, MD a,b, James P

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Badrul A. Chowdhury, MD, PhD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Clinical pharmacology of H1-antihistamines in the skin

Elinor Simons, MDa, William M

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Randomized, double-blind, crossover challenge study in 53 subjects reporting adverse reactions to melon (Cucumis melo) Julia Rodriguez, MDa, Jesus F.

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis Sakari Reitamo, MDa,

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) Christian Möller, MD, PhDa, Sten.

The pattern of atopic sensitization is associated with the development of asthma in childhood Sabina Illi, MPHa,b, Erika von Mutius, MDb, Susanne Lau,

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis Anjuli S. Nayak, MDa, Mark H.

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

The 30th anniversary of the American Board of Allergy and Immunology: Then and now Lynn Des Prez a, Charles E. Reed, MD, Lawrence B. Schwartz, MDb, John.

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis Matthias Volkmar Kopp, MDa, Jens Brauburger,

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis Ellinor Ädelroth, MD, PhDa, Sabina Rak, MD, PhDb,

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing.

Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib Pär Gyllfors,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

National trends in asthma visits and asthma pharmacotherapy,

Larry C. Borish, MDa, Harold S

The environmental predictors of allergic disease

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis Ulrich Wahn, MDa*‡, Eli O. Meltzer, MDb*‡, Albert F. Finn, MDc*‡, Marek L. Kowalski, MD, PhDd‡, Paola Decosta, MDe, Gunilla Hedlin, MDf*, Pierre Scheinmann, MDg*, Claus Bachert, MD, PhDh*, Jose E. Rosado Pinto, MDi*, Carlos Baena-Cagnani, MDj‡, Paul Potter, MDk‡, F. Estelle R. Simons, MDl*, Erik Ruuth, MD, PhDe Journal of Allergy and Clinical Immunology Volume 111, Issue 4, Pages 763-769 (April 2003) DOI: 10.1067/mai.2003.1384 Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 1 Mean (± SE) change in PM -reflective total symptom score (TSS) with modified intention-to-treat (mITT) population. ***P ≤ .0001 versus placebo. Journal of Allergy and Clinical Immunology 2003 111, 763-769DOI: (10.1067/mai.2003.1384) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 2 Twelve-hour PM -reflective individual symptom scores with modified intention-to-treat (mITT) population. All P values are for the treatment group versus placebo. *P < .01. **P < .001. ***P ≤ .0001. Journal of Allergy and Clinical Immunology 2003 111, 763-769DOI: (10.1067/mai.2003.1384) Copyright © 2003 Mosby, Inc. Terms and Conditions

Fig. 3 Daily PM -reflective total symptom score (TSS) during double-blind treatment period—modified intention-to-treat (mITT) population. The arrow above the graph indicates the first point at which the effects of treatment would be observed (Day 2); Day 1 corresponds to the baseline (B) . *P < .01. **P < .001. ***P ≤ .0001. Journal of Allergy and Clinical Immunology 2003 111, 763-769DOI: (10.1067/mai.2003.1384) Copyright © 2003 Mosby, Inc. Terms and Conditions